These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

511 related articles for article (PubMed ID: 22915447)

  • 41. Functional, cognitive and behavioral effects of donepezil in patients with moderate Alzheimer's disease.
    Gauthier S; Feldman H; Hecker J; Vellas B; Emir B; Subbiah P;
    Curr Med Res Opin; 2002; 18(6):347-54. PubMed ID: 12442882
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effects of donepezil dose escalation in Parkinson's patients with dementia receiving long-term donepezil treatment: an exploratory study.
    Ishikawa K; Motoi Y; Mizuno Y; Kubo S; Hattori N
    Psychogeriatrics; 2014 Jun; 14(2):93-100. PubMed ID: 24661498
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial.
    Tariot PN; Farlow MR; Grossberg GT; Graham SM; McDonald S; Gergel I;
    JAMA; 2004 Jan; 291(3):317-24. PubMed ID: 14734594
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Ginkgo biloba and donepezil: a comparison in the treatment of Alzheimer's dementia in a randomized placebo-controlled double-blind study.
    Mazza M; Capuano A; Bria P; Mazza S
    Eur J Neurol; 2006 Sep; 13(9):981-5. PubMed ID: 16930364
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Donepezil for dementia with Lewy bodies: a randomized, placebo-controlled trial.
    Mori E; Ikeda M; Kosaka K;
    Ann Neurol; 2012 Jul; 72(1):41-52. PubMed ID: 22829268
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Donepezil for cognitive impairment in Parkinson's disease: a randomised controlled study.
    Aarsland D; Laake K; Larsen JP; Janvin C
    J Neurol Neurosurg Psychiatry; 2002 Jun; 72(6):708-12. PubMed ID: 12023410
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group.
    Rogers SL; Farlow MR; Doody RS; Mohs R; Friedhoff LT
    Neurology; 1998 Jan; 50(1):136-45. PubMed ID: 9443470
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The beneficial effect of cholinesterase inhibitors on patients suffering from Parkinson's disease and dementia.
    Werber EA; Rabey JM
    J Neural Transm (Vienna); 2001; 108(11):1319-25. PubMed ID: 11768630
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Efficacy and safety of a loading-dose regimen versus a no-loading-dose regimen of metrifonate in the symptomatic treatment of Alzheimer's disease: a randomized, double-masked, placebo-controlled trial. Metrifonate Study Group.
    Jann MW; Cyrus PA; Eisner LS; Margolin DI; Griffin T; Gulanski B
    Clin Ther; 1999 Jan; 21(1):88-102. PubMed ID: 10090427
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The clinical meaningfulness of ADAS-Cog changes in Alzheimer's disease patients treated with donepezil in an open-label trial.
    Rockwood K; Fay S; Gorman M; Carver D; Graham JE
    BMC Neurol; 2007 Aug; 7():26. PubMed ID: 17760991
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Donepezil in patients with subcortical vascular cognitive impairment: a randomised double-blind trial in CADASIL.
    Dichgans M; Markus HS; Salloway S; Verkkoniemi A; Moline M; Wang Q; Posner H; Chabriat HS
    Lancet Neurol; 2008 Apr; 7(4):310-8. PubMed ID: 18296124
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Donepezil: in vascular dementia.
    Goldsmith DR; Scott LJ
    Drugs Aging; 2003; 20(15):1127-36. PubMed ID: 14651435
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cholinergic deficit and response to donepezil therapy in Parkinson's disease with dementia.
    Hiraoka K; Okamura N; Funaki Y; Hayashi A; Tashiro M; Hisanaga K; Fujii T; Takeda A; Yanai K; Iwata R; Mori E
    Eur Neurol; 2012; 68(3):137-43. PubMed ID: 22832236
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Donepezil for dementia due to Alzheimer's disease.
    Birks J; Harvey RJ
    Cochrane Database Syst Rev; 2006 Jan; (1):CD001190. PubMed ID: 16437430
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer's disease.
    Morris JC; Cyrus PA; Orazem J; Mas J; Bieber F; Ruzicka BB; Gulanski B
    Neurology; 1998 May; 50(5):1222-30. PubMed ID: 9595967
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Donepezil for dementia due to Alzheimer's disease.
    Birks JS; Harvey R
    Cochrane Database Syst Rev; 2003; (3):CD001190. PubMed ID: 12917900
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Efficacy of donepezil in mild cognitive impairment: a randomized placebo-controlled trial.
    Salloway S; Ferris S; Kluger A; Goldman R; Griesing T; Kumar D; Richardson S;
    Neurology; 2004 Aug; 63(4):651-7. PubMed ID: 15326237
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Efficacy and Safety of Donepezil in Chinese Patients with Severe Alzheimer's Disease: A Randomized Controlled Trial.
    Jia J; Wei C; Jia L; Tang Y; Liang J; Zhou A; Li F; Shi L; Doody RS
    J Alzheimers Dis; 2017; 56(4):1495-1504. PubMed ID: 28157100
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The efficacy and safety of donepezil in patients with Alzheimer's disease: results of a US Multicentre, Randomized, Double-Blind, Placebo-Controlled Trial. The Donepezil Study Group.
    Rogers SL; Friedhoff LT
    Dementia; 1996; 7(6):293-303. PubMed ID: 8915035
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effects of donepezil on neuropsychiatric symptoms in patients with dementia and severe behavioral disorders.
    Cummings JL; McRae T; Zhang R;
    Am J Geriatr Psychiatry; 2006 Jul; 14(7):605-12. PubMed ID: 16816014
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.